The University of Southampton
University of Southampton Institutional Repository

Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression

Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression
Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression
OBJECTIVE: To examine the hypothesis that increased monocyte tissue factor (mTF) levels may reflect urological tumour presence and progression.

PATIENTS, SUBJECTS AND METHODS: Using a two-stage kinetic chromogenic assay, mTF levels were measured in 60 controls (normal subjects [60] and patients awaiting hernia repair or cholecystectomy [60]), patients with benign and malignant disease of the bladder (73), or prostate (81), and in patients with and without recurrent malignant disease of the bladder (30). The levels were assessed under fresh resting conditions (baseline) and after incubation for 6 h without (unstimulated) and with (stimulated) Escherichia coli endotoxin. Each benign disease group was subdivided into inflammatory and non-inflammatory categories.

RESULTS: Patients with bladder and prostate malignancy showed significantly higher mTF levels than did each control for baseline and stimulated cells. The benign inflammatory groups for both organs had significantly higher mTF levels than had each control for baseline cells. There was no difference between malignant and benign inflammatory groups. Stimulated mTF levels showed better discrimination between the study groups. The mTF levels were associated with histological tumour progression, serum prostate specific antigen level and static bone scan images. Levels were also higher in patients with bladder cancer recurrence than in those with a normal check cystoscopy.

CONCLUSION: Stimulated mTF levels are raised in malignant and inflammatory disease compared with controls and patients with non-inflammatory conditions, and give maximal discrimination between these groups. mTF levels showed an association with tumour grade and other markers of tumour progression.
monocyte tissue factor, urological tumours, progression, benign disease, prognosis
1464-410X
476-482
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Francis, J.L.
54a1f2e1-fd7a-4592-b55c-3c856810b68d
Chisholm, M.
c45aab85-a073-4041-9d3f-f7cd738aae4f
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Francis, J.L.
54a1f2e1-fd7a-4592-b55c-3c856810b68d
Chisholm, M.
c45aab85-a073-4041-9d3f-f7cd738aae4f

Lwaleed, B.A., Francis, J.L. and Chisholm, M. (1999) Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression. BJU International, 83 (4), 476-482. (PMID:10210574)

Record type: Article

Abstract

OBJECTIVE: To examine the hypothesis that increased monocyte tissue factor (mTF) levels may reflect urological tumour presence and progression.

PATIENTS, SUBJECTS AND METHODS: Using a two-stage kinetic chromogenic assay, mTF levels were measured in 60 controls (normal subjects [60] and patients awaiting hernia repair or cholecystectomy [60]), patients with benign and malignant disease of the bladder (73), or prostate (81), and in patients with and without recurrent malignant disease of the bladder (30). The levels were assessed under fresh resting conditions (baseline) and after incubation for 6 h without (unstimulated) and with (stimulated) Escherichia coli endotoxin. Each benign disease group was subdivided into inflammatory and non-inflammatory categories.

RESULTS: Patients with bladder and prostate malignancy showed significantly higher mTF levels than did each control for baseline and stimulated cells. The benign inflammatory groups for both organs had significantly higher mTF levels than had each control for baseline cells. There was no difference between malignant and benign inflammatory groups. Stimulated mTF levels showed better discrimination between the study groups. The mTF levels were associated with histological tumour progression, serum prostate specific antigen level and static bone scan images. Levels were also higher in patients with bladder cancer recurrence than in those with a normal check cystoscopy.

CONCLUSION: Stimulated mTF levels are raised in malignant and inflammatory disease compared with controls and patients with non-inflammatory conditions, and give maximal discrimination between these groups. mTF levels showed an association with tumour grade and other markers of tumour progression.

Full text not available from this repository.

More information

Published date: March 1999
Keywords: monocyte tissue factor, urological tumours, progression, benign disease, prognosis
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 349270
URI: http://eprints.soton.ac.uk/id/eprint/349270
ISSN: 1464-410X
PURE UUID: f5aadbc0-5c58-4b37-abdf-e89f162d883d

Catalogue record

Date deposited: 27 Feb 2013 13:03
Last modified: 16 Jul 2019 21:42

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×